Jump to content

Norverapamil

From Wikipedia, the free encyclopedia
(Redirected from C26H36N2O4)
Norverapamil
Names
IUPAC name
(RS)-2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethylamino]-2-isopropylpentanenitrile
Identifiers
3D model (JSmol)
ChEBI
ChemSpider
ECHA InfoCard 100.060.476 Edit this at Wikidata
EC Number
  • 266-544-8
UNII
  • InChI=1S/C26H36N2O4/c1-19(2)26(18-27,21-9-11-23(30-4)25(17-21)32-6)13-7-14-28-15-12-20-8-10-22(29-3)24(16-20)31-5/h8-11,16-17,19,28H,7,12-15H2,1-6H3 ☒N
    Key: UPKQNCPKPOLASS-UHFFFAOYSA-N ☒N
  • InChI=1/C26H36N2O4/c1-19(2)26(18-27,21-9-11-23(30-4)25(17-21)32-6)13-7-14-28-15-12-20-8-10-22(29-3)24(16-20)31-5/h8-11,16-17,19,28H,7,12-15H2,1-6H3
    Key: UPKQNCPKPOLASS-UHFFFAOYAQ
  • CC(C)C(CCCNCCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
Properties
C26H36N2O4
Molar mass 440.584 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Norverapamil is a calcium channel blocker. It is the main active metabolite of verapamil.[1]

References

[edit]
  1. ^ Christiane Pauli-Magnus, Oliver von Richter, Oliver Burk, Anja Ziegler, Thomas Mettang, Michel Eichelbaum and Martin F. Fromm (2000). "Characterization of the Major Metabolites of Verapamil as Substrates and Inhibitors of P-glycoprotein". Journal of Pharmacology and Experimental Therapeutics. 293 (2): 376–382. PMID 10773005.{{cite journal}}: CS1 maint: multiple names: authors list (link)